Coherus BioSciences Inc (CHRS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
RETAIL-WOMEN'S CLOTHING STORES
CEO:
Denny M. Lanfear
Employees:
350
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA 94065
(650) 649-3530

Coherus BioSciences, Inc. markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. Pipeline products include biosimilars of Humira, Avastin, and Lucentis. Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China.

Data derived from most recent annual or quarterly report
Market Cap 458.89 Million Shares Outstanding77.778 Million Avg 30-day Volume 1.297 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.65
Price to Revenue3.6876 Debt to Equity4.1778 EBITDA-256.43 Million
Price to Book Value12.322 Operating Margin-80.8015 Enterprise Value1.195 Billion
Current Ratio3.643 EPS Growth-3.352 Quick Ratio3.268
1 Yr BETA 1.5747 52-week High/Low 14.11 / 5.58 Profit Margin-87.9189
Operating Cash Flow Growth-124.2836 Altman Z-Score-0.9518 Free Cash Flow to Firm -129.673 Million
Earnings Report2023-05-04

Are you looking for this stock instead?

View SEC Filings from CHRS instead.

View recent insider trading info

Funds Holding CHRS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CHRS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2023-03-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-13:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2022-10-06:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-09-15:
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2022-09-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-20:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-05-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LANFEAR DENNIS M PRESIDENT & CEO

    • Officer
    • Director
    1,174,502 2023-01-20 3

    VEXLER VLADIMIR CHIEF SCIENTIFIC OFFICER

    • Officer
    131,323 2023-01-20 4

    STILWELL MCDAVID CHIEF FINANCIAL OFFICER

    • Officer
    104,243 2023-01-20 3

    MCMICHAEL BRYAN J SEE REMARKS

    • Officer
    26,386 2023-01-20 5

    O'DONNELL-TORMEY JILL

    • Director
    0 2022-05-18 2

    NEWTON CHARLES W.

    • Director
    0 2022-05-04 3

    WAHLSTROM MATS

    • Director
    40,000 2022-02-25 0

    NEWCOMER LEE NISLEY

    • Director
    0 2022-02-02 0

    HEALY JAMES

    • Director
    27,000 2022-01-07 0

    STOLPER MARK

    • Director
    27,000 2022-01-07 0

    TZOUMAKAS KIMBERLY JO

    • Director
    27,000 2022-01-07 0

    ANICETTI VINCENT R CHIEF OPERATING OFFICER

    • Officer
    274,790 2021-07-06 0

    MENDELSON ALAN C

    • Director
    20,000 2021-05-21 0

    VIRET JEAN-FREDERIC CHIEF FINANCIAL OFFICER

    • Officer
    61,295 2021-02-01 0

    NUSSBAUM SAMUEL R MD

    • Director
    0 2021-01-11 0

    LAWLIS V BRYAN

    • Director
    0 2021-01-11 0

    SZELA MARY T

    • Director
    0 2021-01-11 0

    SATVAT ALI J.

    • Director
    0 2020-01-10 0

    RICHARDS CHRISTOS

    • Director
    0 2020-01-10 0

    V-SCIENCES INVESTMENTS PTE LTD

    TEMASEK LIFE SCIENCES PRIVATE LTD

    FULLERTON MANAGEMENT PTE LTD

    TEMASEK HOLDINGS (PRIVATE) LTD

    • 10% Owner
    7,381,116 2019-12-30 0

    HORTON DARLENE P SEE REMARKS

    • Officer
    0 2019-01-18 0

    FINCK BARBARA K CHIEF MEDICAL OFFICER

    • Officer
    37,043 2018-09-10 0

    TROENDLE AUGUST J.

    • Director
    1,940,914 2018-02-01 0

    WATLER PETER K. CHIEF TECHNICAL OFFICER

    • Officer
    5,900 2018-02-01 0

    HERMAN ALAN C. CHIEF SCIENTIFIC OFFICER

    • Officer
    350,624 2017-12-15 0

    FMR LLC

    • SEE REMARK 1
    No longer subject to file 2016-08-08 0

    LILLY ELI & CO

    LILLY VENTURES FUND I LLC

    • FORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2014-11-12 0

    KKR BIOSIMILAR L.P.

    KKR BIOSIMILAR GP LLC

    KKR FUND HOLDINGS L.P.

    KKR FUND HOLDINGS GP LTD

    KKR GROUP HOLDINGS L.P.

    KKR GROUP LTD

    KKR & CO. L.P.

    KKR MANAGEMENT LLC

    KRAVIS HENRY R

    ROBERTS GEORGE R

    • 10% Owner
    No longer subject to file 2014-11-12 0

    DAIICHI SANKYO COMPANY, LTD

    • FORMER 10% OWNER
    No longer subject to file 2014-11-12 0

    COOPERMAN LEON G

    • 10% Owner
    5,893,736 2012-03-27 0

    GOLDSTEIN MICHAEL

    • Director
    59,785 2010-10-15 0

    ROMANO ANTHONY EVP - CHIEF OPERATING OFFICER

    • Officer
    40,637 2010-10-15 0

    FOGARTY JAMES P PRESIDENT AND CEO

    • Officer
    • Director
    125,000 2010-06-24 0

    LEVITT JAY PRESIDENT - FASHION BUG

    • Officer
    42,331 2010-06-08 0

    BENNET RICHARD WILSON III

    • Director
    18,000 2010-04-07 0

    STRANDJORD M JEANNINE

    • Director
    98,195 2009-07-01 0

    ROSSKAMM ALAN

    • Director
    132,263 2009-04-14 0

    WOOLF BRIAN PRESIDENT - LANE BRYANT

    • Officer
    20,000 2009-01-23 0

    HUDSON KATHERINE M

    • Director
    122,222 2008-12-19 0

    CURL YVONNE M

    • Director
    53,187 2008-07-11 0

    DESABATO ANTHONY A EVP - CORP. & LABOR RELATIONS

    • Officer
    115,022 2007-03-26 0

    SPECTER ERIC M EVP - CHIEF FINANCIAL OFFICER

    • Officer
    186,577 2007-03-26 0

    STERN COLIN D EVP, GENERAL COUNSEL & SEC.

    • Officer
    127,500 2007-03-26 0

    SULLIVAN JOHN J VP - CONTROLLER

    • Officer
    68,647 2007-03-26 0

    BARON JOSEPH M EVP/CHIEF OPERATING OFFICER

    • Officer
    189,341 2007-03-26 0

    VARMA GALE H EVP - HUMAN RESOURCES

    • Officer
    103,689 2007-03-26 0

    BOURLON MICHEL EVP-SOURCING

    • Officer
    71,906 2007-03-26 0

    BLOISE JAMES G EVP SUPPLY CHAIN, TECH. & BSC

    • Officer
    87,653 2007-03-26 0

    BERN DORRIT J PRESIDENT & CEO

    • Officer
    • Director
    1,172,612 2007-02-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 22:15:03 UTC 4.5296 0.2904 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 21:45:03 UTC 4.5294 0.2906 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 21:15:03 UTC 4.5294 0.2906 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 20:45:03 UTC 4.5294 0.2906 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 20:15:04 UTC 4.5294 0.2906 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 19:45:03 UTC 4.5294 0.2906 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 19:15:04 UTC 4.5294 0.2906 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 18:45:04 UTC 4.5285 0.2915 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 18:15:03 UTC 4.5285 0.2915 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 17:45:03 UTC 4.5285 0.2915 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 17:15:03 UTC 4.5285 0.2915 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 16:45:03 UTC 4.5285 0.2915 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 16:15:03 UTC 4.5285 0.2915 1900000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 15:45:03 UTC 4.5285 0.2915 1900000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 15:15:03 UTC 4.5285 0.2915 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 14:45:03 UTC 4.5285 0.2915 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 14:15:03 UTC 4.5285 0.2915 1900000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 13:45:03 UTC 4.2919 0.2781 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 13:15:04 UTC 4.2919 0.2781 2100000
    COHERUS BIOSCIENCES INC CHRS 2023-03-24 12:45:03 UTC 4.2919 0.2781 2100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Morningstar Funds Trust- Morningstar Alternatives Fund CHRS -33811.0 shares, $-294155.7 2022-10-31 N-PORT
    Calamos Investment Trust/IL- Calamos Market Neutral Income Fund CHRS -117790.0 shares, $-1024773.0 2022-10-31 N-PORT
    Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund CHRS -34107.0 shares, $-233974.02 2022-11-30 N-PORT
    Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund CHRS -5301.0 shares, $-41983.92 2022-12-31 N-PORT
    AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund CHRS -25900.0 shares, $-205128.0 2022-12-31 N-PORT
    Guidestone Funds- Strategic Alternatives Fund CHRS -11947.0 shares, $-94620.24 2022-12-30 N-PORT
    LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio CHRS -25647.0 shares, $-203124.24 2022-12-31 N-PORT
    JNL Series Trust- JNL Multi-Manager Alternative Fund CHRS -69872.0 shares, $-553386.24 2022-12-31 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Shri Thanedar House Filing 2023-01-30 2023-01-23 S $15,001-$50,000

    Elevate your investments